1
Anderson Christen, Liu Que: Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling. Amylin Pharmaceuticals, Anderson Christen, Liu Que, AMYLIN PHARMACEUTICALS, October 19, 2006: WO/2006/110887 (8 worldwide citation)

The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using ...


2
Ghosh Soumitra Shankar, Lewis Diana Y, Janssen Samuel, Srivastava Ved, Liu Que, Jodka Carolyn M, Soares Christopher J, Lin Qing: Composition and methods for treatment of congestive heart failure. Amylin Pharmaceuticals, Ghosh Soumitra Shankar, Lewis Diana Y, Janssen Samuel, Srivastava Ved, Liu Que, Jodka Carolyn M, Soares Christopher J, Lin Qing, BUTLER James E, December 6, 2007: WO/2007/139941 (6 worldwide citation)

Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the m ...


3
GRUNDY John, BHANOT Sanjay, LIU Que: [fr] ADMINISTRATION DOLIGONUCLÉOTIDES ANTI-SENS DU FACTEUR XI, [en] ADMINISTRATION OF FACTOR XI ANTISENSE OLIGONUCLEOTIDES. GRUNDY John, BHANOT Sanjay, LIU Que, ISIS PHARMACEUTICALS, GINGRICH Brenden, May 16, 2013: WO/2013/070771

[en] Disclosed herein are methods of administering pharmaceutical compositions comprising a modified antisense oligonucleotide for decreasing Factor XI activity and decreasing Factor XI antigen. Also disclosed herein are methods of administering pharmaceutical compositions comprising a modified anti ...